As cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving.
Results from the pivotal phase III BELIEVE trial, which supported the FDA approval of luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, have been published in the New England Journal of Medicine.
The challenge in caring for older patients is developing a risk-adapted strategy that best meets the patients’ identified goals and accounts for a realistic assessment of hematopoietic stem cell transplantation suitability.
Stereotactic ablative radiation reduced disease progression compared with observation in patients with oligometastatic prostate cancer.
As the number of confirmed cases of COVID-19 continues to grow, oncologists from all over the world are working together to stay informed on the latest developments, participate in pivotal research efforts, develop potentially life-saving medications, and share personal experiences faced in practice to ultimately improve patient care.
A new drug application has been submitted to the Taiwan Food and Drug Administration for avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring PDGFRA exon 18 mutations, including PDGFRA D842V mutations, according to CStone Pharmaceuticals, a partner of Blueprint Medicines.
Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.
This has been a difficult time for public health policy and regulatory organizations struggling to deal with rapidly changing and unquestionably serious societal health-related issues and concerns. The list of problems these agencies must tackle is growing, and so are the questions about the strategies that should be used to address these threats.
Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.